Single and Multiple Dose Study in Japanese
Study Details
Study Description
Brief Summary
This study will explore the safety, tolerability, and serum uric acid lowering effect of lesinurad in healthy Japanese males to allow comparison with the Western population.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
While there is extensive clinical experience with lesinurad in the Western population, it is recognized that both intrinsic and extrinsic factors may impact the PK, PD, safety, and dose response in different ethnic populations. The purpose of this study is to explore the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of single and multiple doses of lesinurad in healthy Japanese males, and to allow comparison of these parameters with the Western population.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: 200 mg lesinurad 200 mg lesinurad or placebo fasted and fed |
Drug: Lesinurad
Drug: Placebo
|
| Experimental: 400 mg lesinurad 400 mg lesinurad or placebo fasted and fed |
Drug: Lesinurad
Drug: Placebo
|
| Experimental: 100 mg lesinurad 100 mg lesinurad or placebo fasted and fed |
Drug: Lesinurad
Drug: Placebo
|
| Experimental: 50 mg lesinurad 50 mg lesinurad or placebo fasted and fed |
Drug: Lesinurad
Drug: Placebo
|
| Experimental: 600 mg lesinurad 600 mg lesinurad or placebo fasted and fed |
Drug: Lesinurad
Drug: Placebo
|
Outcome Measures
Primary Outcome Measures
- Incidence of Adverse Events and Changes in Laboratory Parameters [5 to 6 weeks]
- Pharmacokinetic (PK) profile of lesinurad from plasma and urine in terms of AUC, tmax, cmax and t1/2. [Day -1 through 12]
AUC: area under the plasma concentration time curve from zero to 24 hours post dose and from zero to infinity; tmax: time to maximum plasma concentration; cmax: maximum observed plasma concentration t1/2: terminal elimination half life
- Pharmacodynamic (PD) profile of lesinurad from serum and urine in terms of sUA concentration, renal clearance, urine uric acid excretion, and fractional excretion. [Day 1 through 12]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Able to understand the study procedures, the risks involved and willing to provide written Informed Consent before the first study related activity.
-
Healthy adult subjects born in Japan
-
All laboratory parameters should be within normal limits or considered not clinically significant by the investigator.
-
Screening serum uric acid level >= 4.5 mg/dL.
-
Subjects must be free of any clinically significant disease that requires a physician's care and/or would interfere with study evaluations or procedures.
-
Subject does not have clinically relevant abnormalities in blood pressure, heart rate, body temperature, and respiratory rate, as per the Investigator's judgment.
Exclusion Criteria:
-
Positive serology to Human Immunodeficiency Virus (HIV-1 and HIV-2).
-
Positive test for active Hepatitis B or Hepatitis C infection.
-
History of kidney stones.
-
Undergone major surgery within 3 months of Day 1.
-
Subject has received the last dose of an investigational drug (or treatment with a medical device) within 30 days or 5 half-lives (whichever is longer) of the investigational drug prior to Day 1 or are currently participating in another study of an investigational drug (or medical device).
-
Prior exposure to lesinurad (RDEA594) or RDEA806.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Glendale | California | United States | 91206 |
Sponsors and Collaborators
- Ardea Biosciences, Inc.
Investigators
- Study Director: S Bradley, MD, Ardea Biosciences, Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RDEA594-125